Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Temporary elimination of orthostatic hypotension by norepinephrine infusion.

Goldstein DS, Sewell L, Holmes C, Pechnik S, Diedrich A, Robertson D.

Clin Auton Res. 2012 Dec;22(6):303-6. doi: 10.1007/s10286-012-0176-4. Epub 2012 Sep 16.

2.
3.

Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.

Isaacson SH, Skettini J.

Vasc Health Risk Manag. 2014 Apr 3;10:169-76. doi: 10.2147/VHRM.S53983. eCollection 2014. Review.

4.

Diagnosing and treating neurogenic orthostatic hypotension in primary care.

Kuritzky L, Espay AJ, Gelblum J, Payne R, Dietrich E.

Postgrad Med. 2015;127(7):702-15. doi: 10.1080/00325481.2015.1050340. Epub 2015 May 27. Review.

PMID:
26012731
5.

Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.

Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE.

Lancet Neurol. 2016 Aug;15(9):954-966. doi: 10.1016/S1474-4422(16)30079-5. Review.

PMID:
27478953
6.

Pharmacotherapy of autonomic failure.

Shibao C, Okamoto L, Biaggioni I.

Pharmacol Ther. 2012 Jun;134(3):279-86. doi: 10.1016/j.pharmthera.2011.05.009. Epub 2011 Jun 12. Review.

7.

Evaluation and management of orthostatic hypotension.

Lanier JB, Mote MB, Clay EC.

Am Fam Physician. 2011 Sep 1;84(5):527-36. Review.

8.

Confounders of vasovagal syncope: orthostatic hypotension.

Nwazue VC, Raj SR.

Cardiol Clin. 2013 Feb;31(1):89-100. doi: 10.1016/j.ccl.2012.09.003. Review.

9.

L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.

Kaufmann H.

Clin Auton Res. 2008 Mar;18 Suppl 1:19-24. doi: 10.1007/s10286-007-1002-2. Epub 2008 Mar 27. Review.

PMID:
18368303
10.

New developments in the management of neurogenic orthostatic hypotension.

Biaggioni I.

Curr Cardiol Rep. 2014 Nov;16(11):542. doi: 10.1007/s11886-014-0542-z. Review.

PMID:
25303896
11.

Pathophysiology and Treatment of Orthostatic Hypotension in Parkinsonian Disorders.

Sinn DI, Gibbons CH.

Curr Treat Options Neurol. 2016 Jun;18(6):28. doi: 10.1007/s11940-016-0410-9. Review.

PMID:
27138287
12.

Management of neurogenic orthostatic hypotension.

Arbique D, Cheek D, Welliver M, Vongpatanasin W.

J Am Med Dir Assoc. 2014 Apr;15(4):234-9. doi: 10.1016/j.jamda.2013.10.014. Epub 2014 Jan 2. Review.

PMID:
24388946
13.

Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.

Keating GM.

Drugs. 2015 Feb;75(2):197-206. doi: 10.1007/s40265-014-0342-1. Review.

PMID:
25559422
14.

Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management.

Pathak A, Senard JM.

Expert Rev Cardiovasc Ther. 2004 May;2(3):393-403. Review.

PMID:
15151485
15.

Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension.

Baker J, Kimpinski K.

CNS Drugs. 2017 Aug;31(8):653-663. doi: 10.1007/s40263-017-0453-9. Review.

PMID:
28702747
16.

Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions.

Loavenbruck A, Sandroni P.

Curr Med Res Opin. 2015 Nov;31(11):2095-104. doi: 10.1185/03007995.2015.1087988. Epub 2015 Oct 13. Review.

PMID:
26373628
17.

Effect of selected drugs on arterial pressure response to upright posture.

McNay JL.

Cardiology. 1976;61 suppl 1:249-54. Review.

PMID:
788908
18.

Pure autonomic failure.

Brown TP.

Pract Neurol. 2017 Oct;17(5):341-348. doi: 10.1136/practneurol-2016-001559. Epub 2017 Jul 17. Review.

PMID:
28717053

Supplemental Content

Support Center